Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of 22.7 per cent of their body weight. That was only marginally ahead of results for Mounjaro, an existing rival treatment made by Eli Lilly.
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Clinical Trials Arena on MSN4d
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trialThe Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback